In this section, you can review LDL cholesterol reduction results and LDL cholesterol goal attainment results from
comparative clinical trials in which CRESTOR® (rosuvastatin calcium) was used as an adjunct to diet
in patients who switched statin therapy. You can also download the MERCURY II publication.
LDL Cholesterol Reductions vs Other Statins
-
LDL-C reductions in patients at high risk of CHD, switching to CRESTOR vs remaining on atorvastatin
-
-
LDL-C reductions in patients at high risk of CHD, switching to CRESTOR vs remaining on simvastatin
-
-
LDL-C reductions after switching to CRESTOR 10 mg from simvastatin 20 mg in patients at high risk of CHD
-
LDL Cholesterol Goal Attainment vs Other Statins
-
Goal attainment (LDL-C <100 mg/dL) in high-risk patients switching to CRESTOR vs remaining on atorvastatin
-
-
Goal attainment (LDL-C <100 mg/dL) in high-risk patients switching to CRESTOR vs remaining on simvastatin
-
LDL Cholesterol Reductions, Additional Results vs Other Statins
-
Percentage change from baseline LDL-C at 16 weeks in patients switching to CRESTOR vs remaining on atorvastatin
-
-
Percentage change from baseline LDL-C at 16 weeks in patients switching to CRESTOR vs remaining on simvastatin or pravastatin
-
LDL-C reductions in patients at high risk of CHD, switching to CRESTOR vs remaining on atorvastatin
*P<.001 atorvastatin 10 mg switched to CRESTOR 10 mg vs atorvastatin 10 mg;
atorvastatin 20 mg switched to CRESTOR 20 mg vs atorvastatin 20 mg
Mean baseline LDL-C: 167 mg/dL to 169 mg/dL (all arms of trial).
Arm 1 (Weeks 1–16):
CRESTOR 20 mg n=362
Arm 2 (Week 16):
CRESTOR 10 mg n=189
atorvastatin 10 mg n=180
Arm 3 (Week 16):
CRESTOR 20 mg n=184
atorvastatin 20 mg n=182
MERCURY II was a 16-week, randomized, open-label, 2-period, parallel-group, multicenter study. Following a 6-week
dietary lead-in period, patients at high risk of CHD were randomized to 1 of 5 arms: CRESTOR 20 mg, atorvastatin 10 mg, atorvastatin 20 mg,
simvastatin 20 mg, or simvastatin 40 mg once daily (period 1: 8 weeks). Patients then remained on these treatments or were switched as follows:
half from atorvastatin 10 mg and simvastatin 20 mg to CRESTOR 10 mg once daily; half from atorvastatin 20 mg and simvastatin
40 mg to CRESTOR 20 mg once daily (period 2: 8 weeks). Patients had either been treated with CRESTOR, atorvastatin, or simvastatin for
16 weeks or with CRESTOR for 8 weeks following 8 weeks of comparator treatment. The primary end point was percentage of patients achieving
NCEP ATP III LDL-C goal at week 16.
LDL-C reductions in patients at high risk of CHD, switching to CRESTOR vs remaining on simvastatin
*P<.001 simvastatin 20 mg switched to CRESTOR 10 mg vs simvastatin 20 mg;
simvastatin 40 mg switched to CRESTOR 20 mg vs simvastatin 40 mg.
Mean baseline LDL-C: 167 mg/dL to 169 mg/dL (all arms of trial).
Arm 1 (Weeks 1–16):
CRESTOR 20 mg n=362
Arm 4 (Week 16):
CRESTOR 10 mg n=179
simvastatin 20 mg n=185
Arm 5 (Week 16):
CRESTOR 20 mg n=183
simvastatin 40 mg n=183
MERCURY II was a 16-week, randomized, open-label, 2-period, parallel-group, multicenter study. Following a 6-week dietary lead-in period, patients at high risk of CHD were randomized to 1 of 5 arms: CRESTOR 20 mg, atorvastatin 10 mg, atorvastatin 20 mg, simvastatin 20 mg, or simvastatin 40 mg once daily (period 1: 8 weeks). Patients then remained on these treatments or were switched as follows: half from atorvastatin 10 mg and simvastatin 20 mg to CRESTOR 10 mg once daily; half from atorvastatin 20 mg and simvastatin 40 mg to CRESTOR 20 mg once daily (period 2: 8 weeks). Patients had either been treated with CRESTOR, atorvastatin, or simvastatin for 16 weeks or with CRESTOR for 8 weeks following 8 weeks of comparator treatment. The primary end point was percentage of patients achieving NCEP ATP III LDL-C goal at week 16.
LDL-C reductions after switching to CRESTOR 10 mg from simvastatin 20 mg in patients at high risk of CHD
*P<.001 CRESTOR 10 mg vs simvastatin 20 mg.
Mean baseline LDL-C: 169 mg/dL (all arms of trial).
Week 8:
simvastatin 20 mg n=387
Week 16:
CRESTOR 10 mg n=179
simvastatin 20 mg n=185
MERCURY II was a 16-week, randomized, open-label, 2-period, parallel-group, multicenter study. Following a 6-week dietary lead-in period, patients at high risk of CHD were randomized to 1 of 5 arms: CRESTOR 20 mg, atorvastatin 10 mg, atorvastatin 20 mg, simvastatin 20 mg, or simvastatin 40 mg once daily (period 1: 8 weeks). Patients then remained on these treatments or were switched as follows: half from atorvastatin 10 mg and simvastatin 20 mg to CRESTOR 10 mg once daily; half from atorvastatin 20 mg and simvastatin 40 mg to CRESTOR 20 mg once daily (period 2: 8 weeks). Patients had either been treated with CRESTOR, atorvastatin, or simvastatin for 16 weeks or with CRESTOR for 8 weeks following 8 weeks of comparator treatment. The primary end point was percentage of patients achieving NCEP ATP III LDL-C goal at week 16.
Goal attainment (LDL-C <100 mg/dL) in high-risk patients switching to CRESTOR vs remaining on atorvastatin
*P<.001 atorvastatin 10 mg switched to CRESTOR 10 mg vs atorvastatin 10 mg;
atorvastatin 20 mg switched to CRESTOR 20 mg vs atorvastatin 20 mg.
Mean baseline LDL-C: 167 mg/dL (all arms of trial).
Arm 1 (Weeks 1–16):
CRESTOR 20 mg n=362
Arm 2 (Week 16):
CRESTOR 10 mg n=189
atorvastatin 10 mg n=180
Arm 3 (Week 16):
CRESTOR 20 mg n=184
atorvastatin 20 mg n=182
MERCURY II was a 16-week, randomized, open-label, 2-period, parallel-group, multicenter study. Following a 6-week dietary lead-in period, patients at high risk of CHD were randomized to 1 of 5 arms: CRESTOR 20 mg, atorvastatin 10 mg, atorvastatin 20 mg, simvastatin 20 mg, or simvastatin 40 mg once daily (period 1: 8 weeks). Patients then remained on these treatments or were switched as follows: half from atorvastatin 10 mg and simvastatin 20 mg to CRESTOR 10 mg once daily; half from atorvastatin 20 mg and simvastatin 40 mg to CRESTOR 20 mg once daily (period 2: 8 weeks). Patients had either been treated with CRESTOR, atorvastatin, or simvastatin for 16 weeks or with CRESTOR for 8 weeks following 8 weeks of comparator treatment. The primary end point was percentage of patients achieving NCEP ATP III LDL-C goal at week 16.
Goal attainment (LDL-C <100 mg/dL) in high-risk patients switching to CRESTOR vs remaining on simvastatin
*P<.001 simvastatin 20 mg switched to CRESTOR 10 mg vs simvastatin 20 mg;
simvastatin 40 mg switched to CRESTOR 20 mg vs simvastatin 40 mg.
Mean baseline LDL-C: 167 mg/dL (all arms of trial).
Arm 1 (Weeks 1–16):
CRESTOR 20 mg n=362
Arm 4 (Week 16):
CRESTOR 10 mg n=179
simvastatin 20 mg n=185
Arm 5 (Week 16):
CRESTOR 20 mg n=183
simvastatin 40 mg n=183
MERCURY II was a 16-week, randomized, open-label, 2-period, parallel-group, multicenter study. Following a 6-week dietary lead-in period, patients at high risk of CHD were randomized to 1 of 5 arms: CRESTOR 20 mg, atorvastatin 10 mg, atorvastatin 20 mg, simvastatin 20 mg, or simvastatin 40 mg once daily (period 1: 8 weeks). Patients then remained on these treatments or were switched as follows: half from atorvastatin 10 mg and simvastatin 20 mg to CRESTOR 10 mg once daily; half from atorvastatin 20 mg and simvastatin 40 mg to CRESTOR 20 mg once daily (period 2: 8 weeks). Patients had either been treated with CRESTOR, atorvastatin, or simvastatin for 16 weeks or with CRESTOR for 8 weeks following 8 weeks of comparator treatment. The primary end point was percentage of patients achieving NCEP ATP III LDL-C goal at week 16.
Percentage change from baseline LDL-C at 16 weeks in patients switching to CRESTOR vs remaining on atorvastatin
MERCURY I was a 16-week, randomized, open-label, 5-arm, 2-period, multicenter, parallel-group study in patients with hyperlipidemia or mixed dyslipidemia. Patients had a history of CHD or established atherosclerotic disease, type 2 diabetes, or a CHD risk >20% over 10 years. Following a 6-week dietary lead-in period, patients were randomized to 1 of 5 treatment arms: CRESTOR 10 mg, atorvastatin 10 mg, atorvastatin 20 mg, simvastatin 20 mg, or pravastatin 40 mg once daily (period 1: 8 weeks). Patients then remained on these treatments or were switched as follows: half from atorvastatin 10 mg, simvastatin 20 mg, and pravastatin 40 mg to CRESTOR 10 mg once daily; one third of each from atorvastatin 20 mg to CRESTOR 10 mg and 20 mg once daily (period 2: 8 weeks). Primary end point was percentage of patients reaching Joint European Societies’ LDL-C goal <116 mg/dL at week 16.
Percentage change from baseline LDL-C at 16 weeks in patients switching to CRESTOR vs remaining on simvastatin or pravastatin
MERCURY I was a 16-week, randomized, open-label, 5-arm, 2-period, multicenter, parallel-group study in patients with hyperlipidemia or mixed dyslipidemia. Patients had a history of CHD or established atherosclerotic disease, type 2 diabetes, or a CHD risk >20% over 10 years. Following a 6-week dietary lead-in period, patients were randomized to 1 of 5 treatment arms: CRESTOR 10 mg, atorvastatin 10 mg, atorvastatin 20 mg, simvastatin 20 mg, or pravastatin 40 mg once daily (period 1: 8 weeks). Patients then remained on these treatments or were switched as follows: half from atorvastatin 10 mg, simvastatin 20 mg, and pravastatin 40 mg to CRESTOR 10 mg once daily; one third of each from atorvastatin 20 mg to CRESTOR 10 mg and 20 mg once daily (period 2: 8 weeks). Primary end point was percentage of patients reaching Joint European Societies’ LDL-C goal <116 mg/dL at week 16.